Update on Vitamin Supplements for the Prevention of Coronary Disease and Stroke



FREE PREVIEW Log in or buy this issue to read the full article. AAFP members and paid subscribers get free access to all articles. Subscribe now.


FREE PREVIEW Subscribe or buy this issue. AAFP members and paid subscribers get free access to all articles.

Am Fam Physician. 2000 Sep 15;62(6):1359-1366.

  Related Editorial

Dietary antioxidants and folic acid may play a role in the pathophysiology of coronary disease and stroke. We review patient-oriented evidence on the effectiveness of supplementation with antioxidants and/or folic acid in the prevention of myocardial infarction and stroke. Observational data suggest cardiovascular benefit of vitamin E supplementation, but results of controlled clinical trials are inconsistent regarding the effect on nonfatal myocardial infarction. Moreover, studies have not shown a protective effect of vitamin E against fatal myocardial infarction and have not addressed stroke. For vitamin C and folic acid supplementation, observational data are inconsistent and controlled clinical trials are lacking. Thus, the available evidence is insufficient to recommend the routine use of vitamin E, vitamin C or folate supplements for the prevention of myocardial infarction or stroke. The evidence argues against the use of beta carotene supplements for this purpose. The costs and risks associated with these supplements are low, however, and physicians may choose to recommend vitamin E, folate and/or vitamin C supplementation pending conclusive evidence from clinical trials.

Because dietary antioxidants and folic acid (folate) may play a part in the pathophysiology of coronary disease and stroke, interest in the role of vitamin supplements in preventing these diseases is high. This article reviews the evidence from patient-oriented studies to provide information to help physicians decide whether to recommend supplements of antioxidants and/or folate in the prevention of coronary disease and stroke.

Biological Plausibility

Oxidized low-density lipoprotein (LDL) cholesterol attracts and interacts with monocytes, macrophages and platelets to promote atherogenesis in the vascular lining. It also causes endothelial necrosis and interferes with vasorelaxation. Unlike beta carotene, vitamins E and C inhibit LDL oxidation in vitro. Vitamin E reduces monocyte adhesion to endothelium, inhibits platelet activation in vitro and inhibits atherosclerosis in rodents; in humans, angiographic and ultrasonographic studies suggest that vitamin E also inhibits the progression of atherosclerosis.1

Homocysteine is an amino acid product of normal protein metabolism. Folate, vitamin B12 and vitamin B6 are all involved in the metabolism of homocysteine. Deficiencies of one or more of these vitamins can lead to hyperhomocysteinemia.2,3 Homocysteinuria is a rare, congenital enzyme deficiency that results in high serum and urine levels of homocysteine, and persons with this disorder have premature vascular disease and usually die of myocardial infarction (MI), stroke or pulmonary embolus.2

Homocysteine, at five to 10 times the normal concentrations, directly damages endothelium, promotes proliferation of vascular smooth muscle cells, exhibits procoagulant activity and increases collagen synthesis.4 Results of clinical studies reveal that folate and vitamin B12 supplements lower serum homocysteine levels, with mixed results from vitamin B6 supplementation.2,5 Of these three B vitamins, folate has been studied the most and clearly shows the most powerful effect.25

Observational Studies

ANTIOXIDANT VITAMINS

Prospective observational studies (Table 1)614 have addressed whether the intake of vitamin C, vitamin E or beta carotene affects cardiovascular risk after adjustment for known major cardiovascular risk factors. Some studies combined dietary and supplemental intakes, while others attempted to separate these sources. Taken together, the results of these studies do not support any conclusions about potential differential effects by vitamin source.

TABLE 1

Observational Studies of Antioxidant Vitamins

Study Design Outcomes (95% confidence interval) Comments

Nurse's Health6

87,245 women; follow-up for 8 years

Endpoints: MI or stroke

Trend towards stroke prevention

Vitamin E ≥100 IU per day

RR: 0.57 (range: 0.41 to 0.78)

Health Professionals7

39,910 men; follow-up for 4 years

Endpoints: MI or coronary revascularization

Vitamin E ≥100 IU per day

RR: 0.63 (range: 0.47 to 0.84)

Beta carotene ≥14,000 IU per day

RR: 0.30 (range: 0.11 to 0.72)

Beta carotene benefit in smokers only

Vitamin C up to 1,100 mg per day

No effect

Iowa Women8

34,486 women; follow-up for 7 years

Endpoint: fatal MI

Vitamin E ≥10 IU per day

RR: 0.38 (range: 0.18 to 0.80)

Supplement use rare in this cohort

Beta carotene ≥13,000 IU per day

No effect

Vitamin C ≥196 mg per day

No effect

Finnish cohort9

5,133 men/women; follow-up for 14 years

Endpoint: fatal MI

Supplement use rare in this cohort

Vitamin E ≥5 IU per day

RR: 0.35 (range: 0.14 to 0.88)

Benefit among women only

Vitamin C > 90 mg per day

RR: 0.49 (range: 0.32 to 0.98)

Beta carotene

No effect

National Health and Nutrition Examination Survey (NHANES)13

11,348 men/women; follow-up for 10 years

Endpoint: cardiovascular death

Vitamin E intake unaccounted for

Vitamin C ≥50 mg per day

Men—RR: 0.58 (range: 0.53 to 0.82)

Women—RR: 0.75 (range: 0 .55 to 0.99)

Gale, et al.14

730 elderly men/women; follow-up for 20 years

Endpoints: fatal stroke or MI

Vitamin E intake unaccounted for

Vitamin C ≥45 mg per day

RR: 0.50 (range: 0.30 to 0.80), stroke only

Fatal MI—no effect

Established Populations for Epidemiologic

11,178 elderly men/women; follow-up for 6 years

Endpoint: fatal MI

Studies of the Elderly(EPESE)11*

Vitamin E supplement use

RR: 0.53 (range: 0.34 to 0.84)

Vitamin C supplement use

No effect

Scottish Heart Health Study10

11,629 men/women; follow-up for 8 years

Endpoints: MI or coronary revascularization

Vitamin E

No significant effect

Vitamin C

No significant effect

Trend toward protection

Beta carotene

No significant effect

Trend toward protection

The Rotterdam Study12

4,802 men/women; follow-up for 4 years

MI

Vitamin E

No effect

Vitamin C

No effect

Beta carotene

RR: 0.55 (range: 0.34 to 0.83)

Beta carotene benefit in smokers only


MI = myocardial infarction; RR = relative risk.

*—Milligram doses of vitamins E and C in supplements not reported.

—Vitamin doses adjusted for dietary energy intakes—doses in mg per day units not reported.

Information from references 6 through 14.

TABLE 1   Observational Studies of Antioxidant Vitamins

View Table

TABLE 1

Observational Studies of Antioxidant Vitamins

Study Design Outcomes (95% confidence interval) Comments

Nurse's Health6

87,245 women; follow-up for 8 years

Endpoints: MI or stroke

Trend towards stroke prevention

Vitamin E ≥100 IU per day

RR: 0.57 (range: 0.41 to 0.78)

Health Professionals7

39,910 men; follow-up for 4 years

Endpoints: MI or coronary revascularization

Vitamin E ≥100 IU per day

RR: 0.63 (range: 0.47 to 0.84)

Beta carotene ≥14,000 IU per day

RR: 0.30 (range: 0.11 to 0.72)

Beta carotene benefit in smokers only

Vitamin C up to 1,100 mg per day

No effect

Iowa Women8

34,486 women; follow-up for 7 years

Endpoint: fatal MI

Vitamin E ≥10 IU per day

RR: 0.38 (range: 0.18 to 0.80)

Supplement use rare in this cohort

Beta carotene ≥13,000 IU per day

No effect

Vitamin C ≥196 mg per day

No effect

Finnish cohort9

5,133 men/women; follow-up for 14 years

Endpoint: fatal MI

Supplement use rare in this cohort

Vitamin E ≥5 IU per day

RR: 0.35 (range: 0.14 to 0.88)

Benefit among women only

Vitamin C > 90 mg per day

RR: 0.49 (range: 0.32 to 0.98)

Beta carotene

No effect

National Health and Nutrition Examination Survey (NHANES)13

11,348 men/women; follow-up for 10 years

Endpoint: cardiovascular death

Vitamin E intake unaccounted for

Vitamin C ≥50 mg per day

Men—RR: 0.58 (range: 0.53 to 0.82)

Women—RR: 0.75 (range: 0 .55 to 0.99)

Gale, et al.14

730 elderly men/women; follow-up for 20 years

Endpoints: fatal stroke or MI

Vitamin E intake unaccounted for

Vitamin C ≥45 mg per day

RR: 0.50 (range: 0.30 to 0.80), stroke only

Fatal MI—no effect

Established Populations for Epidemiologic

11,178 elderly men/women; follow-up for 6 years

Endpoint: fatal MI

Studies of the Elderly(EPESE)11*

Vitamin E supplement use

RR: 0.53 (range: 0.34 to 0.84)

Vitamin C supplement use

No effect

Scottish Heart Health Study10

11,629 men/women; follow-up for 8 years

Endpoints: MI or coronary revascularization

Vitamin E

No significant effect

Vitamin C

No significant effect

Trend toward protection

Beta carotene

No significant effect

Trend toward protection

The Rotterdam Study12

4,802 men/women; follow-up for 4 years

MI

Vitamin E

No effect

Vitamin C

No effect

Beta carotene

RR: 0.55 (range: 0.34 to 0.83)

Beta carotene benefit in smokers only


MI = myocardial infarction; RR = relative risk.

*—Milligram doses of vitamins E and C in supplements not reported.

—Vitamin doses adjusted for dietary energy intakes—doses in mg per day units not reported.

Information from references 6 through 14.

Seven studies612 examined the association of vitamin E intake (from diet and/or supplement sources) with coronary disease. The results of all of these studies except two10,12 reported a reduction in coronary events associated with higher vitamin E intakes. The only vitamin E study that included stroke6 reported a statistically insignificant trend favoring its use.

Eight studies714 examined the association of vitamin C intake with the incidence of coronary disease. Results were inconsistent between genders and among cohorts, and two of these studies failed to control for vitamin E use.13,14 The results of one study14 that investigated stroke revealed an apparent protective effect of vitamin C.

Five prospective cohort studies710,12 examined associations between coronary disease and beta carotene intake. Results of three studies810 revealed no evidence of a protective effect. In the other two studies,7,12 a protective association was observed only among smokers and ex-smokers.

HOMOCYSTEINE AND FOLATE

Multiple cross-sectional and case-control studies linking plasma homocysteine levels with coronary disease and stroke have been published. The only prospective data come from nested case-control studies involving small sub-samples within large cohort studies. Two recent systematic reviews15,16 have summarized this literature. The first review15 included 15 studies on coronary disease (involving 5,617 persons) and nine studies addressing stroke (involving 2,547 persons) in a meta-analysis. In all but two of the studies included in this analysis, coronary and stroke risks were higher in persons with higher homocysteine levels. The second review16 summarized pertinent studies published since the first review. Results of all but five of the 26 studies in this review revealed a positive relationship between plasma homocysteine and coronary disease and/or stroke.

Since the time of these reviews, results of three more prospective studies have been published.1719 Among all 12 of the prospective studies now reported, five17,18,2022 failed to demonstrate that plasma homocysteine levels were a risk factor for coronary disease or stroke. This lack of consistency among prospective studies makes a causal relationship questionable.

If hyperhomocysteinemia causes cardiovascular disease, then folate supplementation should help prevent it. As yet, there are no reports that link folate intake directly with coronary disease or stroke, but results of interventional studies of folate supplementation have consistently shown a reduction in homocysteine levels, with a plateau effect at a dosage of about 1 mg per day.5,15

SUMMARY OF OBSERVATIONAL STUDIES

The prospective observational evidence is fairly consistent for a protective effect of vitamin E against coronary disease. Evidence about the effect of vitamin E on the risk of stroke is sparse. The evidence linking vitamin C to cardiovascular disease is inconsistent, and a protective effect of beta carotene has been observed only among those who smoke. These studies all addressed primary prevention, and absolute risk reductions appear modest at best.

Based on our calculations, if the observed protective effect of vitamin E is real, 170 to 250 persons would need to take vitamin E supplements (or have high dietary vitamin E intake) for 10 years to prevent one MI or stroke. Observational evidence linking homocysteine with cardiovascular disease is less consistent among prospective studies than in cross-sectional or retrospective analyses.

Controlled Clinical Trials

Observational studies cannot prove or disprove a protective effect because they cannot avoid the real possibility that intake of these vitamins is only a marker for other factors or behaviors that are the true modulators of heart attack and stroke. In the case of antioxidant vitamins and cardiovascular disease, results of seven controlled clinical trials have been reported (Table 2).2330 Results from controlled clinical trials on the effects of folate supplements in the prevention of MI or stroke have yet to be published.

TABLE 2

Placebo-Controlled Clinical Trials of Antioxidant Vitamins

Study Study population Treatment Endpoint(s) Outcomes (95% confidence interval) Comments

Alpha Tocopherol Beta Carotene Cancer Prevention Trial (ATBC)23*24

29,133 male smokers; follow-up for 6 years

Vitamin E, 50 IU per day

MI or stroke

No effect for primary prevention

Vitamin E dose lower than observed as protective in most observational studies

RR: 0.62 (range: 0.41 to 0.96) for nonfatal MI if past history of MI

Same as above

Beta carotene, 20 mg per day

MI or stroke

No significant effect

Trend toward increased risk

Physician's Health25*

22,071 men; follow-up for 12 years

Beta carotene, 50 mg every other day

MI or stroke

No effect

Beta Carotene and Retinol Efficacy Trial (CARET)26*

18,314 men/women; follow-up for 4 years

Beta carotene, 30 mg per day plus vitamin A, 25,000 IU per day

Death—any cause; cardiovascular death

Marginal increases in risk for both outcomes

Chinese Ca Prevention27*

29,584 men/women; follow-up for 5 years

Vitamin E, 30 IU per day, plus beta carotene, 15 mg per day

Cardiovascular death

No significant effect

Vitamin E dose low; trend toward fatal stroke protection

Same as above

Vitamin C, 120 mg per day

Cardiovascular death

No effect

Cambridge Heart Antioxidant Study(CHAOS)28

2,002 men/women with CHD; follow-up for 1.5 years

Vitamin E, 400 to 800 IU per day

Fatal or nonfatal MI

RR: 0.27 (0.11 to 0.47), (nonfatal MI only)

No effect on fatal MI

Heart Outcomes Prevention Evaluation(HOPE)29

9,541 men/women with CVD; follow-up for 4.5 years

Vitamin E, 400 IU per day

MI, stroke or cardiovascular death

No effect on any of these three outcomes

GISSI-Prevenzione30

11,324 men/women secondary prevention after recent MI; follow-up for 3.5 years

Vitamin E, 300 mg per day‡

MI, stroke or cardiovascular death

No effect on any of these three outcomes

Also studied n-3 polyunsaturated fatty acids, which were protective


MI = myocardial infarction; RR = relative risk; CHD = coronary heart disease; CVD = cardiovascular disease.

*—Primary prevention trials.

—Secondary prevention trials.

‡—Vitamin E dosage equivalent: 1 mg = 1.26 IU.

Information from references 23 through 30.

TABLE 2   Placebo-Controlled Clinical Trials of Antioxidant Vitamins

View Table

TABLE 2

Placebo-Controlled Clinical Trials of Antioxidant Vitamins

Study Study population Treatment Endpoint(s) Outcomes (95% confidence interval) Comments

Alpha Tocopherol Beta Carotene Cancer Prevention Trial (ATBC)23*24

29,133 male smokers; follow-up for 6 years

Vitamin E, 50 IU per day

MI or stroke

No effect for primary prevention

Vitamin E dose lower than observed as protective in most observational studies

RR: 0.62 (range: 0.41 to 0.96) for nonfatal MI if past history of MI

Same as above

Beta carotene, 20 mg per day

MI or stroke

No significant effect

Trend toward increased risk

Physician's Health25*

22,071 men; follow-up for 12 years

Beta carotene, 50 mg every other day

MI or stroke

No effect

Beta Carotene and Retinol Efficacy Trial (CARET)26*

18,314 men/women; follow-up for 4 years

Beta carotene, 30 mg per day plus vitamin A, 25,000 IU per day

Death—any cause; cardiovascular death

Marginal increases in risk for both outcomes

Chinese Ca Prevention27*

29,584 men/women; follow-up for 5 years

Vitamin E, 30 IU per day, plus beta carotene, 15 mg per day

Cardiovascular death

No significant effect

Vitamin E dose low; trend toward fatal stroke protection

Same as above

Vitamin C, 120 mg per day

Cardiovascular death

No effect

Cambridge Heart Antioxidant Study(CHAOS)28

2,002 men/women with CHD; follow-up for 1.5 years

Vitamin E, 400 to 800 IU per day

Fatal or nonfatal MI

RR: 0.27 (0.11 to 0.47), (nonfatal MI only)

No effect on fatal MI

Heart Outcomes Prevention Evaluation(HOPE)29

9,541 men/women with CVD; follow-up for 4.5 years

Vitamin E, 400 IU per day

MI, stroke or cardiovascular death

No effect on any of these three outcomes

GISSI-Prevenzione30

11,324 men/women secondary prevention after recent MI; follow-up for 3.5 years

Vitamin E, 300 mg per day‡

MI, stroke or cardiovascular death

No effect on any of these three outcomes

Also studied n-3 polyunsaturated fatty acids, which were protective


MI = myocardial infarction; RR = relative risk; CHD = coronary heart disease; CVD = cardiovascular disease.

*—Primary prevention trials.

—Secondary prevention trials.

‡—Vitamin E dosage equivalent: 1 mg = 1.26 IU.

Information from references 23 through 30.

Neutral or negative effects were reported in all four primary prevention trials.23,2527 However, only two of these included vitamin E and at doses that were only about one half of that associated with reduced cardiovascular risk in observational studies. In the Alpha Tocopherol Beta Carotene Cancer Prevention Trial23 (ATBC), neither vitamin E (50 IU per day) nor beta carotene (20 mg per day) had a significant effect on the risk of a first MI or stroke. In the Beta Carotene and Retinol Efficacy Trial,26 the combination of 30 mg per day of beta carotene plus 25,000 IU per day of vitamin A increased the risk of death from all causes, with a marginally significant increase in the risk of cardiovascular death.

In a randomized trial25 restricted to male physicians, beta carotene at a dosage of 50 mg every other day had no effect on the risk of fatal or nonfatal MI or stroke. Among Chinese men and women in a large cancer prevention trial27 of nutritional supplements, beta carotene (15 mg per day) with vitamin E (30 IU per day) had no effect on coronary deaths (which were rare in this cohort, anyway), but a trend toward fewer strokes was evident. Vitamin C supplementation at a dosage of 120 mg per day also had no effect on cardiovascular mortality.

Four clinical trials24,2830 have addressed the use of antioxidant supplements to prevent MI in patients with known coronary disease; none of these trials addressed the secondary prevention of stroke. In the ATBC trial24 among the subset of male smokers with a past history of MI, the risk of another nonfatal MI in those receiving vitamin E was reduced by 38 percent, with no significant impact on fatal MI. However, the risk of fatal MI in these men was increased with beta carotene use alone or in combination with vitamin E.24 In the Cambridge Heart Antioxidant Study28 of men and women with angiographic coronary disease, 400 to 800 IU per day of vitamin E reduced the risk of nonfatal MI by 73 percent but had no effect on fatal MI.

The Health Outcomes Prevention Evaluation29 study assessed the effect of 400 IU per day of vitamin E on patients with known cardiovascular disease and found no effect on the incidence of MI, stroke or cardiovascular death. Similarly, in the GISSI Prevenzione trial,30 300 mg per day of vitamin E had no effect on subsequent MI, stroke or cardiovascular death rates among patients with a recent history of MI.

SUMMARY OF CLINICAL TRIALS

Taken together, the available evidence from randomized controlled trials fails to demonstrate that antioxidant vitamins or folate supplementation is effective for the prevention of coronary disease or stroke. However, this lack of evidence is due more to a paucity of clinical trials than to negative outcomes.

Secondary prevention of coronary disease with vitamin E looked promising based on the first two trials,24,28 but the efficacy in secondary prevention was not confirmed in either of two larger subsequent trials.29,30 In addition, the mixed evidence for protective effects of vitamin E against nonfatal MI with no evidence of benefit against fatal MI are unexplained, although a lack of power to detect such effects is plausible.

The available evidence argues against the prescription of beta carotene supplements. Currently, there is no evidence from clinical trials that included disease-specific endpoints to support or refute the potential efficacy of folate, and only one study has investigated vitamin C supplementation, with neutral results.27

Safety and Cost of Supplements

If folate or vitamin E supplements prove to reduce cardiovascular risk, the available evidence suggests that vitamin E is best given in a dosage of 100 to 800 IU per day and folate is best given in a dosage of 0.4 to 1 mg per day. The recommended intake of vitamin E is 19 IU per day, and vitamin E doses less than 800 IU per day are safe.31 However, daily doses of vitamin E greater than 800 IU may adversely affect platelet function, and doses greater than 1,200 IU per day may interfere with vitamin K functions and granulocytic responses.3235 The current recommended intake of folate for general health is 0.4 mg per day with a tolerable upper limit of 1 mg per day.36 The only plausible adverse effects of folate at doses up to 1 mg per day would be masking of vitamin B12 deficiency (in those at risk for B12 malabsorption) and possible interference with zinc absorption.37,38

The cardiovascular data on vitamin C are weak but suggest a lower therapeutic threshold of 50 to 100 mg per day. The recommended intake of vitamin C is 75 to 90 mg per day with an upper limit of 2 g per day.31 Vitamin C toxicity is rare at doses less than 5 g per day, although as little as 500 mg per day may promote oxalate kidney stones.39,40 Rebound scurvy is possible after abrupt cessation of large doses.41,42

Thus, the doses of vitamin E, folate and vitamin C that may have cardiovascular benefit are quite safe and inexpensive. The average wholesale price of vitamin E at a dosage of 800 IU per day is about $3.00 per month; vitamin C at a dosage of 500 mg per day and folate at a dosage of 1 mg per day each cost about $1.50 per month wholesale.43

Final Comment

The available evidence is insufficient to recommend the routine use of vitamin E, vitamin C or folate supplements for the prevention of coronary disease or stroke. The evidence argues against the use of beta carotene supplements for this purpose.

Vitamin E at a dose of 100 to 800 IU per day may be useful for secondary prevention, but results from clinical trials are inconsistent. The observational evidence about vitamin C is also inconsistent, and the only reported clinical trial showed no effect. The nonclinical and observational evidence in support of folate supplements is extensive, but evidence from prospective observational studies reveal mixed results (but not harm), and no clinical trial has been completed. On the other hand, the cost and safety profiles for vitamin C, vitamin E and folate supplements are all favorable for empiric use at doses we have discussed.

A similar review regarding antioxidant use has recently been published in this journal.44 We believe that the evidence supporting the use of antioxidants in the prevention of coronary disease is weaker than this earlier review suggests, and our opinions are more aligned with those of an accompanying editorialist.45 A heart-healthy diet, emphasizing fruits and vegetables containing antioxidants and B vitamins, may be the best advice in the end.

The Authors

KEVIN A. PEARCE, M.D., M.P.H., is the Michael Rankin professor of family medicine at the University of Kentucky College of Medicine, Lexington. He received his medical degree from the University of Florida College of Medicine, Gainesville, and completed his residency in Family Practice at the Medical College of Virginia/Fairfax Hospital, Fairfax. He received his master of public health degree in epidemiology at the University of Minnesota School of Public Health, Minneapolis.

MARIA G. BOOSALIS, PH.D., M.P.H., R.D., L.D., is an associate professor in the Division of Clinical Nutrition at the University of Kentucky, Lexington. She received her doctor of philosophy degree at the University of Minnesota, Minneapolis and her master of public health degree at the University of California, Berkeley. She is a licensed and registered dietitian with extensive experience in nutritional research and education.

BRYAN YEAGER, PHARM.D., is an assistant professor in the Department of Family Medicine at the Kentucky Clinic and the University of Kentucky College of Pharmacy, Lexington. Dr. Yeager received his bachelor of science degree in pharmacy from the University of Missouri–Kansas City and his doctor of pharmacy degree from the University of Texas, Austin. He completed a postdoctoral residency in Primary Care and Geriatrics at the University of Texas, Austin. He served three years as clinical pharmacy specialist with Kaiser Permanente and as an assistant professor at the University of Colorado, Denver.

Please address correspondence to Kevin A. Pearce, M.D., M.P.H., Department of Family Practice, Room K-302, Kentucky Clinic, University of Kentucky, Lexington, KY 40526–0284. Reprints are not available from the authors.

REFERENCES

1. Diaz MN, Frei B, Vita JA, Keaney JF Jr. Antioxidants and atherosclerotic heart disease. N Engl J Med. 1997;337:408–16.

2. Malinow MR, Bostom AG, Krauss RM. Homo-cyst(e)ine, diet, and cardiovascular diseases: a statement for healthcare professionals from the Nutrition Committee, American Heart Association. Circulation. 1999;99:178–82.

3. Abby SL, Harris IM, Harris KM. Homocysteine and cardiovascular disease. J Am Board Fam Pract. 1998;11:391–8.

4. Kuller LH, Evans RW. Homocysteine, vitamins, and cardiovascular disease [Editorial]. Circulation. 1998;98:196–9.

5. Clarke R. Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials. BMJ. 1998;316:894–8.

6. Stampfer MJ, Hennekens CH, Manson JE, Colditz GA, Rosner B, Willett WC. Vitamin E consumption and the risk of coronary disease in women. N Engl J Med. 1993;328:1444–9.

7. Rimm EB, Stampfer MJ, Ascherio A, Giovannucci E, Colditz GA, Willett WC. Vitamin E consumption and the risk of coronary heart disease in men. N Engl J Med. 1993;328:1450–6.

8. Kushi LH, Folsom AR, Prineas RJ, Mink PJ, Wu Y, Bostick RM. Dietary antioxidant vitamins and death from coronary heart disease in postmenopausal women. N Engl J Med. 1996;334:1156–62.

9. Knekt P, Reunanen A, Jarvinen R, Seppanen R, Heliovaara M, Aromaa A. Antioxidant vitamin intake and coronary mortality in a longitudinal population study. Am J Epidemiol. 1994;139:1180–9.

10. Todd S, Woodward M, Tunstall-Perdoe H, Bolton-Smith C. Dietary antioxidant vitamins and fiber in the etiology of cardiovascular disease and all-causes mortality: results the Scottish Heart Health Study. Am J Epidemiol. 1999;150:1073–80.

11. Losonczy KG, Harris TB, Havlik RJ. Vitamin E and vitamin C supplement use and risk of all-cause and coronary heart disease mortality in older persons: the Established Populations for Epidemiologic Studies of the Elderly. Am J Clin Nutr. 1996;64:190–6.

12. Klipstein-Grobusch K, Geleijnse JM, den Breeijen JH, Boeing H, Hofman A, Grobbee DE, et al. Dietary antioxidants and risk of myocardial infarction in the elderly: the Rotterdam Study. Am J Clin Nutr. 1999;69:261–6.

13. Enstrom JE, Kanim LE, Klein MA. Vitamin C intake and mortality among a sample of the United States population. Epidemiology. 1992;3:194–202.

14. Gale CR, Martyn CN, Winter PD, Cooper C. Vitamin C and risk of death from stroke and coronary heart disease in cohort of elderly people. BMJ. 1995;310:1563–6.

15. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. JAMA. 1995;274:1049–57.

16. Refsum H, Ueland PM, Nygard O, Vollset SE. Homocysteine and cardiovascular disease. Annu Rev Med. 1998;49:31–62.

17. Folsom AR, Nieto FJ, McGovern PG, Tsai MY, Malinow MR, Eckfeldt JH, et al. Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins: the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 1998;98:204–10.

18. Evans RW, Shaten BJ, Hempel JD, Cutler JA, Kuller LH. Homocyst(e)ine and risk of cardiovascular disease in the Multiple Risk Factor Intervention Trial. Arterioscler Thromb Vasc Biol. 1997;17:1947–53.

19. Ridker PM, Manson JE, Buring JE, Shih J, Matias M, Hennekens CH. Homocysteine and risk of cardiovascular disease among postmenopausal women. JAMA. 1999;281:1817–21.

20. Verhoef P, Hennekens CH, Allen RH, Stabler SP, Willett WC, Stampfer MJ. Plasma total homocysteine and risk of angina pectoris with subsequent coronary artery bypass surgery. Am J Cardiol. 1997;79:799–801.

21. Verhoef P, Hennekens CH, Malinow MR, Kok FJ, Willett WC, Stampfer MJ. A prospective study of plasma homocyst(e)ine and risk of ischemic stroke. Stroke. 1994;25:1924–30.

22. Alfthan G, Pekkanen J, Jauhiainen M, Pitkaniemi J, Karvonen M, Tuomilehto J, et al. Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study. Atherosclerosis. 1994;106:9–19.

23. Virtamo J, Rapola JM, Ripatti S, Heinonen OP, Taylor PR, Albanes D, et al. Effect of vitamin E and beta carotene on the incidence of primary nonfatal myocardial infarction and fatal coronary heart disease. Arch Intern Med. 1998;158:668–75.

24. Rapola JM, Virtamo J, Ripatti S, Huttunen JK, Albanes D, Taylor PR, et al. Randomised trial of alphatocopherol and beta-carotene supplements on incidence of major coronary events in men with previous myocardial infarction. Lancet. 1997;349:1715–20.

25. Hennekens CH, Buring JE, Manson JE, Stampfer M, Rosner B, Cook NR, et al. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med. 1996;334:1145–9.

26. Omenn GS, Goodman GE, Thornquist MD, Balmes J, Cullen MR, Glass A, et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med. 1996;334:1150–5.

27. Blot WJ, Li JY, Taylor PR, Guo W, Dawsey S, Wang GQ, et al. Nutrition intervention trials in Linxian, China: supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population. J Natl Cancer Inst. 1993;85:1483–92.

28. Stephens NG, Parsons A, Schofield PM, Kelly F, Cheeseman K, Mitchinson MJ. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet. 1996;347:781–6.

29. Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P. Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;345:154–60.

30. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. GISSI-Prevenzione Investigators. Lancet. 1999;354:447–55.

31. Dietary reference intakes for vitamin C, vitamin E, selenium and carotenoids: a report of the Panel on Dietary Antioxidants and Related Compounds, Subcommittees on Upper Reference Levels of Nutrients and of Interpretation and Use of Dietary Reference Intakes, and the Standing Committee on the Scientific Evaluation of Dietary Reference Intake, Food and Nutrition Board; Institute of Medicine Washington DC: National Academy Press 2000.

32. Prasad JS. Effect of vitamin E supplementation on leukocyte function. Am J Clin Nutr. 1980;33:606–8.

33. Corrigan JJ. Coagulation problems related to vitamin E. Am J Pediatr Hematol Oncol. 1979;1:169–73.

34. Beahner RL, Boxer LA, Ingraham LM, Butterick C, Haak RA. The influence of vitamin E on human polymorphonuclear cell metabolism and function. Ann N Y Acad Sci. 1982;393:237–50.

35. Meydani M. Vitamin E. Lancet. 1995;345:170–5.

36. Dietary reference intakes for thiamin, riboflavin, niacin, vitamin B6, folate, vitamin B12, pantothenic acid, biotin, and choline: a report of the Standing Committee on the Scientific Evaluation of Dietary Refrence Intake and its panel on folate, other B vitamins, choline and Subcommittee on Upper Reference Levels of Nutrients, Food and Nutrition Board, Institute of Medicine, Washington, DC: National Academy Press, 2000.

37. Herbert V. Recommended dietary intakes (RDI) of vitamin B12 in humans. Am J Clin Nutr. 1987;45:671–8.

38. Arnaud J, Favier A, Herrmann MA, Pilorget JJ. Effect of folic acid and folinic acid on zinc absorption. Ann Nutr Metab. 1992;36:157–61.

39. Jacob RA. Vitamin C In: Shils ME, Olson JA, Shike M, eds. Modern nutrition in health and disease. 8th ed. Philadelphia: Lea & Febiger, 1994:432–48.

40. Urivetzky M, Kessais D, Smith A. Ascorbic acid overdosing: a risk factor for calcium oxalate nephrolithiasis. J Urol. 1992;147:1215–8.

41. Omaye ST, Skala JH, Jacob RA. Rebound effect with ascorbic acid in adult males [Letter]. Am J Clin Nutr. 1988;48:379–80.

42. Gerster H, Moser U. Is high does vitamin C associated with systemic conditioning? Nutr Res. 1988;8:1327–2.

43. 2000 Drug Topics Redbook. Montvale, N.J.: Medical Economics, 2000:690,859,861.

44. Adams AK, Wermuth EO, McBride PE. Antioxidant vitamins and the prevention of coronary heart disease. Am Fam Physician. 1999;60:895–904.

45. Kininghan R. The value of antioxidant vitamin supplements [Editorial]. Am Fam Physician. 1999;60:742,744.

Members of various medical faculties develop articles for “Practical Therapeutics.” This article is one in a series coordinated by the Department of Family Practice at the University of Kentucky College of Medicine, Lexington. Guest editors of the series are Bryan F. Yeager, Pharm.D., Thomas Armsey, M.D., and Samuel C. Matheny, M.D., M.P.H.


Copyright © 2000 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions


Article Tools

  • Print page
  • Share this page
  • AFP CME Quiz

Information From Industry

More in Pubmed

Navigate this Article